Homepage
Author:
BioNxt Solutions Inc.
Posted Date:
April 14, 2026
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
BioNxt Solutions Inc.
April 14, 2026
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
BioNxt Solutions Inc.
April 7, 2026
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
BioNxt Solutions Inc.
March 30, 2026
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
BioNxt Solutions Inc.
March 17, 2026
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
BioNxt Solutions Inc.
February 17, 2026
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
BioNxt Solutions Inc.
February 8, 2026
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
BioNxt Solutions Inc.
January 28, 2026
